Ablative RT protects immune responses

Abstract

highest risk, those with del 17p had a lower overall response rate. Further improvements for this high-risk group will require prospective assessment, not only of response rate (which should no longer be an acceptable primary end point for randomized phase 3 induction trials) but also time to progression (TTP), CR duration, and ultimately OS among a group of patients treated in a similar fashion. 11 This is the only way we can correctly identify the impact of risk stratification in an era of novel therapies, and the only way by which we can make myeloma therapy less risky.